Martine Rothblatt, chairperson and chief executive officer of United Therapeutics, sold 8,160 shares of common stock on November 5, 2026, for a total of about $4.33 million, according to a Form 4 filing dated November 6, 2026. The shares sold at prices ranging from $562.18 to $591.84.
The sales were made under a pre-arranged Rule 10b5-1 trading plan that Rothblatt adopted on November 7, 2025. Concurrently, she exercised options to buy 9,500 shares at $117.76 per share, a total of about $1.12 million. The source says those options vested in equal installments on March 15, 2021, 2022 and 2023.
After these transactions, Rothblatt directly holds 40,513 shares. The filing also lists indirect holdings through family trusts and by her spouse, including 326,403 shares in trusts where she shares investment power and is a beneficiary, and 81,410 stock options held indirectly through a family trust.
The source reports that the stock trades near $562, up 25% over the past year. It cites InvestingPro analysis suggesting the shares may be overvalued at current levels. That view is attributed to InvestingPro and is not a finding of the filing.
Separately, the source reports that United Therapeutics posted record third-quarter revenue of $832.5 million, above an estimate of $785.44 million. Earnings per share were $5.71, below an anticipated $6.21. Tyvaso revenue reached $503.8 million. Raymond James raised its price target to $720 from $717 and kept an Outperform rating. Wells Fargo raised its target to $703 from $700 and kept an Overweight rating.